Figure 6.

Neoadjuvant therapy with CBDCA and anti-PD-1 antibodies increases the frequencies of memory CD8⁺ T cells in secondary breast cancers. Secondary tumors were collected for flow cytometry analysis at Day 35 after the primary tumor implantation. (A) Gating strategies for memory CD8⁺ T cells, which were defined as CD3⁺CD8⁺CD4⁻CD62L⁻CD44^high cells. Treatment of CBDCA combined anti-PD-1 antibodies elevated memory CD8⁺ T cells in 4T1 (B), EMT6 (C), and E0771 (D) tumors. n = 8 per group from one of triplicated experiments. ****p < 0.0001, by two-tail student t-tests.